Ryan Barrett, MD
Ophthalmology · Boise, IDNPI 1982994844
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,515, 2.9 times the $874 reported in 2019. Among ophthalmology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $50.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$1K
- Bausch & Lomb Americas Inc.$927
- Bausch & Lomb, A Division Of Bausch Health US, LLC$596
- Alcon$569
- Harrow Eye, LLC$562
- Novartis$540
- plus $3K from 14 others
Across 2 payments — averaging $2300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$4K
- Ivantis, Inc$1K
What the payments were for
- Speaking & faculty fees$260%
- Travel & lodging$3936%
- Food & beverage$6,35794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 7 | $1,060 |
| Bausch & Lomb Americas Inc. | 17 | $927 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $596 |
| Alcon | 13 | $569 |
| Harrow Eye, LLC | 7 | $562 |
| Novartis | 31 | $540 |
| Glaukos Corporation | 8 | $502 |
| Rxsight Inc | 8 | $485 |
| Sight Sciences, Inc. | 9 | $365 |
| Tarsus Pharmaceuticals, Inc. | 4 | $302 |
| Shire North American Group Inc | 2 | $131 |
| Kala Pharmaceuticals, Inc. | 2 | $129 |
| NEW World Medical,inc. | 2 | $129 |
| Aerie Pharmaceuticals, Inc. | 1 | $114 |
| Sun Pharmaceutical Industries Inc. | 2 | $112 |
| AbbVie | 4 | $98 |
| Ivantis, Inc | 3 | $65 |
| Amgen | 3 | $56 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Dompe US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$471
- Hydrus Microstent$394
- STELLARIS$274
- XIIDRA$229
- XDEMVY$215
- Voyager DSLT$148
- IC-8 Apthera IOL$147
- ENVISTA TORIC$141
- VICTUS$141
- ENVISTA$117
- Rhopressa$114
- Rocklatan$114
- RXSIGHT CONTACT LENS$113
- RXSIGHT INJECTOR CARTRIDGE$113
- RXSIGHT INJECTOR HANDPIECE$113
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$113
- LIGHT ADJUSTABLE LENS (LAL)$113
- MIEBO$111
- EYSUVIS$104
How this compares
$6,776 in reported general payments places this provider in the 95th percentile of 60 ophthalmology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 24 | $789,680 |
| XiidraLifitegrast | 35 | $27,504 |
| Prednisolone Acetate | 779 | $22,911 |
| RestasisCyclosporine | 21 | $15,499 |
| Loteprednol Etabonate | 72 | $12,258 |
| Cyclosporine | 35 | $9,633 |
| Ketorolac Tromethamine | 459 | $9,372 |
| MoxifloxacinMoxifloxacin Hcl | 193 | $6,510 |
| ValacyclovirValacyclovir Hcl | 76 | $5,199 |
| Ofloxacin | 435 | $5,098 |
| Fluorometholone | 63 | $4,956 |
| Doxycycline Hyclate | 42 | $2,033 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $1,192 |
| ErythromycinErythromycin Base | 102 | $1,185 |
| Timolol Maleate | 44 | $1,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $16 | $789,68024 claims |
| Bausch & Lomb Americas Inc.Xiidra | $927 | $27,50435 claims |
| AbbVieRestasis | $98 | $15,49921 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $596 | $12,25872 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 ophthalmology providers in Idaho.
Other ophthalmology in Boise
- Adam ReynoldsBoise$47K
- Landon GrangeBoise$5K
- Jacob MongBoise$5K
- Ali Torab ParhizBoise$5K
- Gregory KentBoise$4K
- Mark HollingsheadBoise$3K
- Matthew NealeBoise$3K
- Denise CappsBoise$2K
- Scott LarsonBoise$2K
- Mark BoernerBoise$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.